title: Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir.
abstract: Enhanced human immunodeficiency virus (HIV)-specific immunity may be required for HIV eradication. Administration of autologous, ex vivo expanded, virus-specific, cytotoxic T-lymphocytes derived from HIV-infected patients on suppressive antiretroviral therapy (HXTCs) are a powerful tool for proof-of-concept studies. Broadly specific, polyclonal HXTCs resulting from ex vivo expansion demonstrated improved control of autologous reservoir virus compared to bulk CD8(+) T cells in viral inhibition assays. Furthermore, patient-derived HXTCs were able to clear latently infected autologous resting CD4(+) T cells following exposure to the latency-reversing agent, vorinostat. HXTCs will be ideal reagents to administer with precise control in future in vivo studies in combination with latency-reversing agents.
authors.affiliation: Department of Medicine.
authors.forename: Julia A
authors.initials: JA
authors.lastname: Sung
authors.affiliation: Department of Molecular Virology and Microbiology, Department of Immunology, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas.
authors.forename: Sharon
authors.initials: S
authors.lastname: Lam
authors.affiliation: Department of Medicine.
authors.forename: Carolina
authors.initials: C
authors.lastname: Garrido
authors.affiliation: Department of Medicine.
authors.forename: Nancie
authors.initials: N
authors.lastname: Archin
authors.affiliation: Department of Molecular Virology and Microbiology, Department of Immunology, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas.
authors.forename: Cliona M
authors.initials: CM
authors.lastname: Rooney
authors.affiliation: Department of Cellular Therapy, Children's National Medical Center, Washington, District of Columbia.
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Bollard
authors.affiliation: Department of Medicine Department of Microbiology and Immunology Department of Epidemiology, University of North Carolina Chapel Hill, Chapel Hill.
authors.forename: David M
authors.initials: DM
authors.lastname: Margolis
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use; D002478:Cells, Cultured; D018920:Coculture Techniques; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology / Q000627:therapeutic use; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000821:virology; D000077337:Vorinostat
chemical_list: D019380:Anti-HIV Agents; D006877:Hydroxamic Acids; D000077337:Vorinostat
keywords: HIV T cells; HIV cure; HIV eradication; HIV immunology; adoptive T-cell therapy; ex vivo expanded T cells; latent reservoir; vorinostat